AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Change in Management 2 Sep - AGM approved Swanith Kapoor as independent director and Aditya Arora’s 5-year reappointment from 30 Sept 2026.
Source: Bse
Kwality Pharmaceuticals Limited (KPL)
Small CapPharma stocks · Small cap · NSE
Kwality Pharmaceuticals Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 19 Oct, 05:50 pm ISTDetails
Quote19 Oct, 05:50 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result16 Aug, 01:42 am IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
73BullishSMA20 +5.1% / mo · MACD − · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 56
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
KPLD candles · FIT view+102.5%Latest close ₹3366.00 on 2026-10-19
Daily history is available from 2026-04-20; the requested 1Y window is partially covered.
Bar
-1.7%
RSI
44
MACD hist
-47.06
52W pos
76%
2026-10-19O ₹3425.70H ₹3500.00L ₹3340.30C ₹3366.00Vol 28,887 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
KPLNifty PharmaNifty 500
- KPL
- +22.7%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- +28.3 pp
Chart stats
19 Oct 2026- From 52W high
- -14.8%
- 52W range position
- 76%
- ATR (14)
- 5.1%
- Volume vs 20D
- 0.80x
- Avg traded value
- ₹13.2 Cr
- 20D price channel
- ₹3,226.6 - ₹3,949
₹3,949
₹1,561 - ₹3,949
₹172.6
Latest completed session
20-session average
50.6% annualized volatility
Research snapshot
What the evidence says now
Mixed fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Momentum only
Trend is strong but fundamentals do not support a clean investment thesis.
U-Score
Legacy · FAIR VALUE54
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Excellent90
Revenue +46.0% · PAT +116.7% YoY
Technical
Bullish73
Price trend and sector-relative-strength timing.
Valuation
Legacy model+4.2%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence84
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Excellent · 90/100Rev +46% YoY · PAT +117% YoY · margin expansion · operating leverage
Filed 30 Jun 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹162 Cr | +46.0% | +3.2% |
| EBITDA | ₹41 Cr | +70.8% | +5.1% |
| Operating margin | 25.0% | +300 bps | +0 bps |
| PAT | ₹26 Cr | +116.7% | +4.0% |
| PAT margin | 16.1% | +524 bps | +13 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 46.30
- P/B
- 11.39
- EV/EBITDA
- 25.23
- Market Cap
- 3781.00Cr
Profitability
- ROE
- 22.60%
- ROCE
- 24.10%
- ROA
- 13.68%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 14.00%
- EPS 5Y
- 35.00%
- Revenue 3Y
- 26.00%
- EPS 3Y
- 29.00%
Balance Sheet
- Debt/Equity
- 0.39
- Interest Coverage
- 12.27×
- Altman Z
- 8.65
- Book Value
- 320.00
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 4/5
- OCF
- 17.00 Cr
- EPS TTM
- 78.11
Shareholding
- Promoter Hold
- 54.86%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 90%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 503+35.9% vs prev
Net Profit
₹ CrLatest: 67.0+67.5% vs prev
Return on Equity
%Latest: 20.2+33.6% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend unclear. RSI 44. Wait for confirmation.
- SMA20 rising (~4.9% over last month) — short-term momentum positive.
- RSI(14) at 44 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 15% off 52W high · 116% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
94
RS percentile
Insufficient history
1M return
-3.0%
3M return
+22.7%
6M return
+105.0%
1Y return
-
RS 1D
0
RS 20D
-
Sector rank
#1
Industry rank
#17
Stage evidence
- At least 170 daily sessions are required for the trend-stage read.
50-DMA
price below
200-DMA
unavailable
Sector
leading
Industry
leading
Partial-history RS: the 3M and 6M weights are re-normalised because 12M history is unavailable.
Relative-strength line vs Nifty 500 (base 100)
127 observations
19 Oct 2026Value 210.02-0.06%
RS vs Nifty 500210
Valuation & peers
U-Score 54 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Valuation & peers
U-Score 54 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Premium Compounder
Fundamental score breakdown
U band · FAIR VALUEValuation2/30
Growth18/25
Quality17/20
Balance Sheet9/15
Cash Flow4/10
Piotroski
8/9 (+5)
Penalties
-1
Raw sum
54
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
54/100 · legacy band FAIR VALUE
Positive drivers
- Piotroski is strong at 8/9.
- Quality contributes 17/20 to the score.
- Growth contributes 18/25 to the score.
Main drags
- Penalty bucket subtracts 1 points.
- Valuation is weaker at 2/30; verify the latest quarterly trend.
- Cash flow is weaker at 4/10; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
46.3
PB
11.4
EV/EBITDA
25.2
ROE
22.6%
ROCE
24.1%
FCF Yield
—
Debt/Equity
0.4
MoS
+4.2%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
54
Previous: 54
Legacy U-Score band
FAIR VALUE
Previous: FAIR VALUE
Margin of safety
+4.2%
Previous: +4.2%
Score history
12 stored score snapshots. Latest stored move: +0 points.
20 Oct 2026
v4.3-runtime-valuation
52
52
52
52
52
52
54
54
54
54
54
54
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹749.93
-348.8% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹3,514.95
+4.2% MoS
PEG
1.42
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
SMSPHARMA
Small
SMS Pharmaceuticals Limited
Healthcare Services
match 169
35
43.7
14.3%
-27%
WATCHLIST
UNICHEMLAB
Small
Unichem Laboratories Limited
Healthcare Services
match 167
66
30.6
3.2%
+74%
UNDERVALUED
RPGLIFE
Small
RPG Life Sciences Limited
Healthcare Services
match 165
57
41.0
19.3%
+13%
FAIR VALUE
ORCHPHARMA
Small
Orchid Pharma Limited
Healthcare Services
match 165
33
320.0
1.5%
-846%
WATCHLIST
LINCOLN
Small
Lincoln Pharmaceuticals Limited
Healthcare Services
match 165
57
11.8
12.3%
+32%
FAIR VALUE
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Kwality Pharmaceuticals Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
84Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 97th percentile of the scored universe and 95th percentile within Pharma. No major sub-score weakness stands out.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
22 docs text-extracted · 2 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
97th percentile
overall median 67 · Pharma: 95th pctile, median 70 · Small: 98th pctile, median 66
Evidence depth
Financial-only
22 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
67
acceptable · profit to cash conversion
Balance sheet
89
strong · leverage and solvency
Discipline
98
strong · capital discipline
Results
95
strong · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸4 years of positive FCF.
- ▸ROCE is 24.1%.
- ▸4/4 latest quarters had positive YoY revenue growth.
Trust risks
- ▸No major Trust Lite risk flags.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Kwality Pharmaceuticals Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Concall transcriptAug 2026
Aug 2026 · Transcript
Source: Bse
Concall transcriptAug 2026
Aug 2026 · Transcript
Source: Bse
Investor presentationAug 2026
Aug 2026 · PPT
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 12 Aug - Newspaper Publication of Notice of 43rd Annual General Meeting.
Source: Bse
Announcement
Compliances-Reg.24(A)-Annual Secretarial Compliance 30 May - Submitted Annual Secretarial Compliance Report for FY2026; prior delayed filing penalty of Rs.2,360 noted.
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2026 from bse
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.